Effect of early and focused benzodiazepine therapy on length of stay in severe alcohol withdrawal syndrome

Jin A. Lee, Jeremiah J. Duby, Christine S Cocanour

Research output: Contribution to journalArticle

Abstract

Objective: Current evidence supports symptom-triggered therapy for alcohol withdrawal syndrome (AWS). Early, escalating therapy with benzodiazepines (BZD) appears to decrease ICU length of stay (LOS); however, the effect on hospital LOS remains unknown. The hypothesis of this study is that focused BZD treatment in the first 24 h will decrease hospital LOS. Design: Pre–post cohort study. Setting: Academic medical center. Patients: This study included patients with severe AWS. The pre-intervention cohort (PRE) was admitted between January and November 2015. The post-intervention cohort (POST) was admitted between April 2016 and March 2017. Severe AWS was defined as patients requiring diazepam doses of >30 mg. Focused treatment was defined as >50% of total diazepam usage within the first 24 h of recognition of AWS. Intervention: In the PRE group, patients received symptom-triggered, escalating doses of diazepam and phenobarbital based on their Richmond Agitation-Sedation Scale (RASS). In the POST group, patients received a revised, time-limited course of therapy: escalating doses of BZD and phenobarbital were given during a 24-h loading phase, and all therapy was discontinued after a 72-h tapering phase. The SHOT scale was used as an adjunct to RASS to assess non-agitation symptoms of AWS and guide additional diazepam doses. Measurements and main results: The primary outcome was hospital LOS; secondary outcomes included ICU LOS, BZD use, and ventilator-free days. Five hundred thirty-two patients were treated using the AWS protocol; 113 experienced severe AWS. The PRE (n = 75) and POST (n = 38) groups were evenly matched in age, sex, history of AWS, and severity of illness. There was a substantial difference in POST patients who received focused treatment (51.3% vs. 73.7%, p =.03). The POST group had a significant decrease in hospital LOS (14.0 vs. 9.8 days, p =.03) and ICU LOS (7.4 vs. 4.4 days, p =.03). Conclusion: Early, focused management of severe AWS was associated with a decrease in ICU and hospital LOS.

Original languageEnglish (US)
JournalClinical Toxicology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Benzodiazepines
Length of Stay
Alcohols
Intensive care units
Diazepam
Therapeutics
Phenobarbital
Substance Withdrawal Syndrome
Mechanical Ventilators
Secondary Prevention
Cohort Studies

Keywords

  • alcohol
  • Alcohol withdrawal
  • benzodiazepine
  • critical care
  • delirium
  • phenobarbital

ASJC Scopus subject areas

  • Toxicology

Cite this

Effect of early and focused benzodiazepine therapy on length of stay in severe alcohol withdrawal syndrome. / Lee, Jin A.; Duby, Jeremiah J.; Cocanour, Christine S.

In: Clinical Toxicology, 01.01.2019.

Research output: Contribution to journalArticle

@article{74e1f7b49b444cb58c4709e4b26e511f,
title = "Effect of early and focused benzodiazepine therapy on length of stay in severe alcohol withdrawal syndrome",
abstract = "Objective: Current evidence supports symptom-triggered therapy for alcohol withdrawal syndrome (AWS). Early, escalating therapy with benzodiazepines (BZD) appears to decrease ICU length of stay (LOS); however, the effect on hospital LOS remains unknown. The hypothesis of this study is that focused BZD treatment in the first 24 h will decrease hospital LOS. Design: Pre–post cohort study. Setting: Academic medical center. Patients: This study included patients with severe AWS. The pre-intervention cohort (PRE) was admitted between January and November 2015. The post-intervention cohort (POST) was admitted between April 2016 and March 2017. Severe AWS was defined as patients requiring diazepam doses of >30 mg. Focused treatment was defined as >50{\%} of total diazepam usage within the first 24 h of recognition of AWS. Intervention: In the PRE group, patients received symptom-triggered, escalating doses of diazepam and phenobarbital based on their Richmond Agitation-Sedation Scale (RASS). In the POST group, patients received a revised, time-limited course of therapy: escalating doses of BZD and phenobarbital were given during a 24-h loading phase, and all therapy was discontinued after a 72-h tapering phase. The SHOT scale was used as an adjunct to RASS to assess non-agitation symptoms of AWS and guide additional diazepam doses. Measurements and main results: The primary outcome was hospital LOS; secondary outcomes included ICU LOS, BZD use, and ventilator-free days. Five hundred thirty-two patients were treated using the AWS protocol; 113 experienced severe AWS. The PRE (n = 75) and POST (n = 38) groups were evenly matched in age, sex, history of AWS, and severity of illness. There was a substantial difference in POST patients who received focused treatment (51.3{\%} vs. 73.7{\%}, p =.03). The POST group had a significant decrease in hospital LOS (14.0 vs. 9.8 days, p =.03) and ICU LOS (7.4 vs. 4.4 days, p =.03). Conclusion: Early, focused management of severe AWS was associated with a decrease in ICU and hospital LOS.",
keywords = "alcohol, Alcohol withdrawal, benzodiazepine, critical care, delirium, phenobarbital",
author = "Lee, {Jin A.} and Duby, {Jeremiah J.} and Cocanour, {Christine S}",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/15563650.2018.1542701",
language = "English (US)",
journal = "Clinical Toxicology",
issn = "1556-3650",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Effect of early and focused benzodiazepine therapy on length of stay in severe alcohol withdrawal syndrome

AU - Lee, Jin A.

AU - Duby, Jeremiah J.

AU - Cocanour, Christine S

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: Current evidence supports symptom-triggered therapy for alcohol withdrawal syndrome (AWS). Early, escalating therapy with benzodiazepines (BZD) appears to decrease ICU length of stay (LOS); however, the effect on hospital LOS remains unknown. The hypothesis of this study is that focused BZD treatment in the first 24 h will decrease hospital LOS. Design: Pre–post cohort study. Setting: Academic medical center. Patients: This study included patients with severe AWS. The pre-intervention cohort (PRE) was admitted between January and November 2015. The post-intervention cohort (POST) was admitted between April 2016 and March 2017. Severe AWS was defined as patients requiring diazepam doses of >30 mg. Focused treatment was defined as >50% of total diazepam usage within the first 24 h of recognition of AWS. Intervention: In the PRE group, patients received symptom-triggered, escalating doses of diazepam and phenobarbital based on their Richmond Agitation-Sedation Scale (RASS). In the POST group, patients received a revised, time-limited course of therapy: escalating doses of BZD and phenobarbital were given during a 24-h loading phase, and all therapy was discontinued after a 72-h tapering phase. The SHOT scale was used as an adjunct to RASS to assess non-agitation symptoms of AWS and guide additional diazepam doses. Measurements and main results: The primary outcome was hospital LOS; secondary outcomes included ICU LOS, BZD use, and ventilator-free days. Five hundred thirty-two patients were treated using the AWS protocol; 113 experienced severe AWS. The PRE (n = 75) and POST (n = 38) groups were evenly matched in age, sex, history of AWS, and severity of illness. There was a substantial difference in POST patients who received focused treatment (51.3% vs. 73.7%, p =.03). The POST group had a significant decrease in hospital LOS (14.0 vs. 9.8 days, p =.03) and ICU LOS (7.4 vs. 4.4 days, p =.03). Conclusion: Early, focused management of severe AWS was associated with a decrease in ICU and hospital LOS.

AB - Objective: Current evidence supports symptom-triggered therapy for alcohol withdrawal syndrome (AWS). Early, escalating therapy with benzodiazepines (BZD) appears to decrease ICU length of stay (LOS); however, the effect on hospital LOS remains unknown. The hypothesis of this study is that focused BZD treatment in the first 24 h will decrease hospital LOS. Design: Pre–post cohort study. Setting: Academic medical center. Patients: This study included patients with severe AWS. The pre-intervention cohort (PRE) was admitted between January and November 2015. The post-intervention cohort (POST) was admitted between April 2016 and March 2017. Severe AWS was defined as patients requiring diazepam doses of >30 mg. Focused treatment was defined as >50% of total diazepam usage within the first 24 h of recognition of AWS. Intervention: In the PRE group, patients received symptom-triggered, escalating doses of diazepam and phenobarbital based on their Richmond Agitation-Sedation Scale (RASS). In the POST group, patients received a revised, time-limited course of therapy: escalating doses of BZD and phenobarbital were given during a 24-h loading phase, and all therapy was discontinued after a 72-h tapering phase. The SHOT scale was used as an adjunct to RASS to assess non-agitation symptoms of AWS and guide additional diazepam doses. Measurements and main results: The primary outcome was hospital LOS; secondary outcomes included ICU LOS, BZD use, and ventilator-free days. Five hundred thirty-two patients were treated using the AWS protocol; 113 experienced severe AWS. The PRE (n = 75) and POST (n = 38) groups were evenly matched in age, sex, history of AWS, and severity of illness. There was a substantial difference in POST patients who received focused treatment (51.3% vs. 73.7%, p =.03). The POST group had a significant decrease in hospital LOS (14.0 vs. 9.8 days, p =.03) and ICU LOS (7.4 vs. 4.4 days, p =.03). Conclusion: Early, focused management of severe AWS was associated with a decrease in ICU and hospital LOS.

KW - alcohol

KW - Alcohol withdrawal

KW - benzodiazepine

KW - critical care

KW - delirium

KW - phenobarbital

UR - http://www.scopus.com/inward/record.url?scp=85061195108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061195108&partnerID=8YFLogxK

U2 - 10.1080/15563650.2018.1542701

DO - 10.1080/15563650.2018.1542701

M3 - Article

C2 - 30729859

AN - SCOPUS:85061195108

JO - Clinical Toxicology

JF - Clinical Toxicology

SN - 1556-3650

ER -